Cancers, sickle cell, cystic fibrosis, blindness, HIV, Huntington's disease, and many more are all diseases that scientists believe genetic modification through Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) can solve. However, this process in the scientific community has brought up many ethical concerns. What diseases should take research priority? How will you ensure class access while still maintaining funding? What guidelines should be in place to prevent this technology from being abused? This committee will have to find solutions to not only these questions but many more.